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Eﬀect of the Glucagon-like Peptide-1 Analogue Exenatide Extended
Release in Cats with Newly Diagnosed Diabetes Mellitus
A. Riederer, E. Zini, E. Salesov, F. Fracassi, I. Padrutt, K. Macha, T.M. St€ockle, T.A. Lutz, and
C.E. Reusch
Background: Exenatide extended release (ER) is a glucagon-like peptide-1 analogue that increases insulin secretion, inhi-
bits glucagon secretion and induces satiation in humans with type 2 diabetes mellitus. The use of exenatide ER is safe and
stimulates insulin secretion in healthy cats.
Objectives: The objective of this study is to assess the safety of exenatide ER and its eﬀect on body weight, remission and
metabolic control in newly diagnosed diabetic cats receiving insulin and a low-carbohydrate diet.
Animals: Thirty client-owned cats.
Methods: Prospective placebo-controlled clinical trial. Cats were treated with exenatide ER or 0.9% saline, administered
SC, once weekly. Both groups received insulin glargine and a low-carbohydrate diet. Exenatide ER was administered for
16 weeks, or in cats that achieved remission it was given for 4 weeks after discontinuing insulin treatment. Nonparametric
tests were used for statistical analysis.
Results: Cats in the exenatide ER and placebo groups had transient adverse signs including decreased appetite (60% vs.
20%, respectively, P = .06) and vomiting (53% vs. 40%, respectively, P = .715). Body weight increased signiﬁcantly in the
placebo group (P = .002), but not in cats receiving exenatide ER. Cats on exenatide ER achieved remission or good meta-
bolic control in 40% or 89%, respectively, whereas in control cats percentages were 20% or 58% (P = .427 and P = .178,
respectively).
Conclusion and clinical importance: Exenatide ER is safe in diabetic cats and does not result in weight gain. Our pilot
study suggests that, should there be an additional clinically relevant beneﬁcial eﬀect of exenatide ER in insulin-treated cats
on rate of remission and good metabolic control, it would likely approximate 20% and 30%, respectively.
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Incretins, such as glucagon-like peptide-1 (GLP-1)and glucose-dependent insulinotropic polypeptide
(GIP), have been the focus of recent studies because of
their beneﬁcial role in glucose homeostasis. Incretins are
gastrointestinal hormones released in response to food
intake that increase glucose-dependent insulin secretion
in various species and have been shown to stimulate
pancreatic b-cell proliferation in rodents.1,2 Addition-
ally, they inhibit glucagon secretion, slow gastric empty-
ing, induce satiation, and promote weight loss.2
However, the half-lives of GLP-1 and GIP are only a
few minutes because they are rapidly cleaved by dipep-
tidylpeptidase-4 (DPP-4).2,3 Incretin-based therapies
have been developed for humans with type 2 diabetes
mellitus (DM). They include GLP-1 receptor analogues
that are resistant to rapid degradation of DPP-4, such
as liraglutide and exenatide or exenatide extended
release (ER), and DPP-4 inhibitors, such as sitagliptin
and vildagliptin, which decrease the degradation of
endogenous GLP-1. Exenatide ER, which requires only
once weekly dosing in humans with type 2 DM, was
more eﬃcacious at decreasing glycated hemoglobin, and
it improved metabolic control and promoted weight loss
more often than DPP-4 inhibitors.4 Exenatide ER
resulted in greater improvements in metabolic control,
induced nausea and vomiting less frequently than
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exenatide (which must be given twice daily), but injec-
tion site irritation was more common.5,6 Furthermore,
exenatide ER currently is considered an eﬀective
second-line treatment to metformin in humans with
type 2 DM because it rarely induces hypoglycemia
when used as monotherapy.4–6
To date, the biology and eﬀects of incretins have
been investigated only in healthy cats. In 1 study, GLP-
1 increased after PO glucose administration.7,8 The
DPP-4 inhibitors were shown to decrease plasma gluca-
gon concentration and to enhance insulin secretion in
cats.9,10 Administration of exenatide, exenatide ER, or
liraglutide caused glucose-dependent insulin secretion,
and a decrease in body weight occurred after the
administration of exenatide and liraglutide in cats.11–14
A recent comparison of incretin-based treatments in
cats showed that exenatide and exenatide ER had more
pronounced eﬀects on insulin secretion than sitaglip-
tin.15 Furthermore, exenatide ER was considered a bet-
ter option than exenatide or sitagliptin because it is
administered only once weekly and has fewer adverse
eﬀects.15
The goal of the present study was to determine
whether the administration of exenatide ER is safe in
newly diagnosed diabetic cats treated with insulin glar-
gine and a low-carbohydrate diet. In addition, the eﬀect
of exenatide ER on body weight, remission rate and
metabolic control was investigated.
Materials and Methods
Animals
This prospective clinical trial used newly diagnosed diabetic cats
admitted from January 2013 to January 2015. The diagnosis of DM
was based on clinical signs and laboratory test results.16 Cats were
excluded if they had received insulin or other antidiabetic medica-
tion for >4 weeks before admission, if glucocorticoids or progesta-
gens had been given during the previous 3 months or if a concurrent
disease such as renal failure, gastrointestinal disorder, heart disease,
another endocrinopathy, or neoplasia was diagnosed. Diabetic cats
with ketoacidosis or pancreatitis were included in the study if clinical
signs resolved and their general condition improved within 48 hours
of treatment. All cats underwent a thorough evaluation including
physical examination, blood tests, and urinalysis (Table 1), blood
pressure measurement, abdominal and thoracic radiography, and
abdominal ultrasonography. A cutoﬀ concentration of >5.3 lg/L
was used for Spec fPL concentration.a For 1,2-o-dilauryl-rac-gly-
cero-3-glutaric acid-(60-methylresoruﬁn) ester (DGGR)-lipase activ-
ity, the cutoﬀ was set at >26 U/L based on the interval previously
established in healthy cats (8–26 U/L).17 For insulin-like growth fac-
tor 1 (IGF-1), a cutoﬀ concentration of >1000 ng/mL was used in
accordance with laboratory guidelines.b The study was approved by
authorities in Switzerland (permission: 122/2011, 118/2014) and in
Italy (permission: 16/79/2014, CE17/02/14). Informed consent was
provided by owners.
Treatment
Enrolled cases were alternately assigned to 1 of 2 treatment
groups; the assignment sequence was known to the veterinarian.
Both groups received insulin glarginec and a low-carbohydrate diet.d
The initial insulin dose was 1.0 IU q12 h in cats weighing <4 kg and
1.5–2.0 IU q12 h in cats ≥4 kg. One group received exenatide ERe
(200 lg/kg) and the other 0.33 mL of 0.9% saline solution (placebo);
both treatments were administered SC once weekly. Owners were
taught how to prepare and inject the exenatide ER or placebo but, as
opposed to the supervising veterinarians, were unaware of the treat-
ment group. If owners found this task problematic, a veterinarian
administered the weekly injections.
Exenatide ER was administered for 16 weeks or, in cats that
achieved diabetic remission, it was given for 4 weeks after discon-
tinuing insulin treatment.
Follow-up
Successive follow-up evaluations were scheduled 1, 3, 6, 10, and
16 weeks after starting exenatide ER or placebo. Each evaluation
included assessment of clinical signs, physical examination ﬁnd-
ings, blood analysis (Table 1) and generation of a glucose curve.
Owners were instructed to perform home monitoring of blood glu-
cose concentrations every 1–2 weeks starting 3 weeks after enroll-
ment. To complete all curves, capillary blood glucose
concentrations were measured every 2 hours for 8–12 hours using
a validated portable blood glucose meter.18 The insulin dose was
adjusted based on clinical signs and results of physical examina-
tion, glucose curves, and serum fructosamine concentration; the
goal was to resolve clinical signs of DM and to obtain curves with
blood glucose concentrations ranging between 80 and 270 mg/dL
and fructosamine concentrations between 350 and 450 lmol/L.19
In cats that achieved remission, the insulin dose was decreased in
increments of 0.5 IU per treatment, once weekly. The last dosage
before insulin was discontinued was 0.5 IU once daily, for at least
1 week. The frequency, onset and duration of remission were
recorded in both groups. The rate of metabolic control was evalu-
ated at the end of the study. Criteria used to deﬁne remission and
good metabolic control are presented in Table 2.
The frequency of hypoglycemia, deﬁned as a blood glucose
curve concentration ≤65 mg/dL, was determined. If owners
observed clinical signs compatible with hypoglycemia (increased
appetite, restlessness, weakness, unsteady gait, loss of conscious-
ness, or twitching), they were instructed to measure capillary blood
glucose concentration and to oﬀer food or administer honey.
The median insulin dose per kg per day given during the study
period was calculated for each cat. Two calculations were done; in
1 of them, the phases of remission were excluded, in the other 1,
the phases of remission were included.
Statistical Analysis
Normality of datasets for continuous and ordered categorical
variables was evaluated using the Shapiro-Wilk normality test.
Parameters with or without normal distribution were analyzed
with parametric and nonparametric tests, respectively. Accord-
ingly, data are presented as mean and standard deviation or as
median and range. Distribution of sex and breed, frequency of
Table 1. Blood and urine examinations at baseline and
during all follow-up examinations.
Blood analysis Baseline Follow-up
Complete blood cell count + +
Biochemical proﬁle + +
Fructosamine + +
T4 +
Spec fPL + +
IGF-1 +
Urinalysis with UPC and culture +
UPC, urine protein-to-creatinine ratio.
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cases treated with antidiabetic medications before inclusion, and
frequency of ketoacidosis recorded at admission were compared
between cats receiving exenatide ER and placebo using Fisher’s
exact test. The same test was used to compare the frequency of
adverse eﬀects and of hypoglycemic episodes, the rate and onset of
remission, and the rate of good metabolic control between groups.
This test also was used to compare the frequency of remission or
good metabolic control between cats that had increased and
decreased body weight within each treatment group, if suﬃciently
represented. Diﬀerences between groups for age, body weight, and
laboratory results recorded at admission and for daily insulin
dosage given over the 16-week study period were analyzed using
the Mann-Whitney U-test or t-test. The same tests were used to
compare concentrations of fructosamine, Spec fPL, DGGR-lipase,
and creatinine concentrations between groups at each follow-up
evaluation. Within each group, diﬀerences in body weight, body
condition score (BCS)f and fructosamine, Spec fPL, DGGR-lipase,
and creatinine concentrations between baseline and the end of the
study were evaluated using the Wilcoxon signed rank test or
paired t-test. A commercial software programg was used. Signiﬁ-
cance was set at P < .05.
Results
Animals
Of 52 cats with newly diagnosed DM admitted during
the study period, 30 cats fulﬁlled the inclusion criteria
and were enrolled. Twenty-three were excluded because
of acromegaly, hyperadrenocorticism, hyperthyroidism,
hypertrophic cardiomyopathy, mesenteric lymph node
abscess, neoplasia, pancreatitis, prior corticosteroid
administration, relapse of diabetes or because they had
received insulin for >4 weeks before admission. Each
treatment group consisted of 15 cats. There were no sig-
niﬁcant diﬀerences between the 2 groups with regard to
age, body weight, distribution of breeds, sex, or fre-
quency of cats previously treated with antidiabetic med-
ication (Table 3).
On admission, 9 cats had ketoacidosis, which
resolved within 1–2 days of treatment; 3 were allocated
to the exenatide ER group and 6 to placebo. The fre-
quency of ketoacidosis did not diﬀer between groups
(P = .427). None of the cats died during the study.
Adverse eﬀects
Adverse eﬀects recorded in cats treated with exe-
natide ER and placebo are documented in Table 4.
Most of the gastrointestinal adverse eﬀects were self-
limiting. In 1 cat that vomited 4 weeks after enrollment,
the referring veterinarian prescribed cimetidine. Vomit-
ing subsided, but recurred during week 10, at which
time exenatide ER treatment was discontinued. This cat
was in good metabolic control 12 weeks after admis-
sion, but did not achieve remission. The frequency of
adverse eﬀects did not diﬀer between groups (Table 4).
Skin lesions were not observed at the injection site of
exenatide ER or placebo-treated cats. One cat treated
with exenatide ER developed nonpruritic histiocytic
panniculitis, which was deemed unrelated to drug
administration because it was 5–10 cm away from the
injection site.
Hypoglycemia
Fourteen of 15 cats (93.3%) treated with exenatide
ER and 12 of 15 cats (80%) treated with placebo had
episodes of hypoglycemia based on blood glucose
curves; the frequency of hypoglycemic episodes did not
diﬀer between groups (P = .598). Median glucose con-
centration during hypoglycemia was 47 mg/dL (range,
25–65) in the exenatide ER group and 50 mg/dL (range,
29–63) in the placebo group. Most of the cats did not
have clinical signs of hypoglycemia. However, 2 cats
with hypoglycemia in the exenatide ER group showed
clinical signs including decreased appetite, vomiting,
and lethargy which disappeared after PO administration
of honey. Episodes of hypoglycemia were observed
more often in weeks 6 and 7 in the exenatide ER group
and in weeks 8 to 12 in the placebo group (Fig 1),
although signiﬁcant diﬀerences were not identiﬁed.
Laboratory Results and Insulin Dosage
Baseline results of a CBC, biochemical proﬁle, urinal-
ysis, and blood pressure measurement did not diﬀer
between groups (Table 5); positive urine culture was
obtained in 1 (6.7%) cat in the exenatide ER group and
in 2 (13.3%) in the placebo group.
Table 2. Criteria used to deﬁne remission and good
metabolic control in cats with DM.19,20
Endpoint
Clinical
signs
Fructosamine
(lmol/L)
Glucose
(mg/dL)
Insulin
treatment
Remission Absent <350 72–162 No (for
≥4 weeks)
Good
metabolic
control
Absent 350–450 80–270 Yes
Table 3. Signalment of diabetic cats and pretreatment
with antidiabetic medications before inclusion in the
study.
Animals
Exenatide ER
(n = 15)
Placebo
(n = 15) P-value
Age in years
Median (range) 9.3 (4.3–14.0) 10 (2.6–15.0) .468
Mean (SD) 9.0 (3.2) 9.8 (3.7)
Body weight in kg
Median (range) 5.3 (4.4–7.4) 4.5 (2.7–8.3) .110
Mean (SD) 5.5 (1.0) 4.9 (1.5)
Domestic short-
or longhair
12 (80%) 14 (93.3%) .598
Purebred 3 (20%) 1 (6.7%)
Neutered male 9 (60%) 5 (33.3%) .143
Intact male 1 (6.7%) 0 (0%)
Spayed female 5 (33.3%) 10 (66.7%)
Pretreatment* 8 (53.3%) 10 (66.7%) .710
SD, standard deviation.
*Antidiabetic medications received before inclusion.
Exenatide Extended Release in Diabetic Cats 3
In cats treated with exenatide ER, the median fruc-
tosamine concentration was 620 lmol/L (range, 402–
883) at baseline and 361 lmol/L (range, 267–483) after
16 weeks. In the placebo group, the median fruc-
tosamine concentration was 582 lmol/L (range, 438–
878) at baseline and 377 lmol/L (range, 256–718) after
16 weeks. A signiﬁcant decrease in serum fructosamine
concentration was observed in both groups (P = .001,
each). Diﬀerences between groups were not identiﬁed at
any time point.
In both groups at the end of the study, concentrations
of Spec fPL (exenatide ER, 1.8 lg/L; range, 0.6–25.4;
placebo, 2.15 lg/L; range, 1.0–14.3; P = .115 and
P = .650, respectively) and DGGR-lipase (exenatide
ER, 19 U/L; range, 10–89; placebo, 18.5 U/L; range, 12–
56; P = .372 and P = .479, respectively) did not diﬀer
from baseline concentrations (Table 5). There was no dif-
ference in the concentration of either enzyme between
groups at any time point (Fig 2). In the exenatide ER
group, baseline Spec fPL concentration was higher than
normal in 3 (20%) cats and remained increased through-
out the study. The Spec fPL was higher than normal at
16 weeks in 1 of the 12 (8.3%) cats with a baseline Spec
fPL concentration ≤5.3 lg/L. In the placebo group, the
baseline Spec fPL concentration was higher than normal
in 5 (33.3%) cats, and it remained increased throughout
the study in 2 of them. Two of 10 (20%) cats with initial
Spec fPL concentrations ≤5.3 lg/L had higher than nor-
mal Spec fPL concentrations after 16 weeks (Fig 2A).
The concentration of serum DGGR-lipase was measured
in 23 of the 30 cats. In the exenatide ER group, baseline
serum DGGR-lipase concentration was higher than nor-
mal in 4 of 11 (36.4%) and remained increased through-
out the study in 3 of them. In the placebo group, baseline
serum DGGR-lipase concentration was higher than nor-
mal in 5 of 12 (41.7%) cats and remained increased
throughout the study in 4 of them (Fig 2B). The concen-
tration of serum DGGR-lipase did not increase by the
end of the study in any of the cats that had normal base-
line concentrations. Cats with increased Spec fPL or
DGGR-lipase concentrations did not have obvious clini-
cal signs or ultrasonographic evidence of pancreatitis.
In the exenatide ER group, serum creatinine concen-
tration was slightly above the reference range in 1 (6.7%)
cat at baseline but it normalized by the end of the study.
Serum creatinine concentration increased signiﬁcantly
from baseline (Table 5) to the end of the study in both
groups (exenatide ER, 1.4 mg/dL; range, 1.1–1.9; pla-
cebo, 1.4 mg/dL; range, 1.0–1.9; P = .012 and P = .005,
respectively). In only 1 cat per group however did it
slightly exceed the reference range. Diﬀerences between
groups were not identiﬁed at any time point.
The median baseline concentration of IGF-1 did not
diﬀer signiﬁcantly between the exenatide ER and pla-
cebo groups (Table 5). One cat of each group had an
IGF-1 concentration >1000 ng/mL at week 0 (exenatide
ER, 1163 ng/mL; placebo, 1041 ng/mL). At week 16,
increased IGF-1 concentrations decreased to normal in
1 cat (exenatide ER, 660 ng/mL) and remained
increased in the other (placebo, 1136 ng/mL). None of
the cats developed clinical signs of acromegaly; these
cats had no organ enlargement on abdominal ultra-
sonography and the cat in the exenatide ER group had
a normal pituitary gland on computed tomography of
the head. These 2 cats achieved remission at weeks 8
and 10, respectively, and still are in remission at the
time of writing (after approximately 1 year).
The median insulin dose administered to cats receiv-
ing exenatide ER or placebo throughout the entire
study did not diﬀer if phases of remission were excluded
(exenatide ER, 0.41 IU/kg/day; range, 0.11–0.88; pla-
cebo, 0.38 IU/kg/day; range: 0.22–1.5; P = .663; Fig 3).
The median insulin dose administered throughout the
Table 4. Type, time of occurrence, and duration of adverse eﬀects in diabetic cats treated with exenatide ER or pla-
cebo.
Adverse eﬀect
Exenatide ER Placebo
P-valueCats (n = 15) Dpi
Between
week
Cats
(n = 15) Dpi
Between
week
Decreased appetite 9 (60%) 1–3 1–10 3 (20%) 0–7 2–6 .060
Vomiting 8 (53.3%) 1–4 0–15 6 (40%) 1–6 0–16 .715
Diarrhea 1 (6.7%) 6 1–14 3 (20%) 1–3 1–14 .598
Increased sleeping 5 (33.3%) 1–3 1–6 1 (6.7%) 1–3 0–6 .169
Hiding in dark areas 3 (20%) 0–3 0–3 1 (6.7%) 1 9 .598
Dpi, days postinjection.
Fig 1. Number of diabetic cats with episodes of hypoglycemia
during the 16-week study period.
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entire study in cats also did not diﬀer if phases of
remission were not excluded from the calculation (exe-
natide ER, 0.36 IU/kg/day; range, 0.07–0.88; placebo,
0.33 IU/kg/day; range, 0.13–1.5; P = 0.494).
Remission and Metabolic Control
Remission of DM was achieved in 6 (40%) cats trea-
ted with exenatide ER and in 3 (20%) cats treated with
placebo (P = .427). All cats that achieved remission had
no relapse of DM at the end of the study. In the exe-
natide ER group, remission occurred 10–14 weeks (me-
dian, 11 weeks) after initiation of treatment, and in the
placebo group, 8–10 weeks (median, 10) after initiation
of treatment. The onset of remission did not diﬀer
between groups (Table 6). Good metabolic control was
obtained in 8 of 9 (88.9%) nonremission cats in the exe-
natide ER group and in 7 of 12 (58.3%) nonremission
cats in the placebo group (P = .178). If cats in remis-
sion were grouped together with those achieving good
metabolic control, 14 of 15 (93.3%) diabetic cats treated
with exenatide ER had remission or good metabolic
control compared with 10 of 15 (66.7%) diabetic cats
treated with placebo (P = .169). In the exenatide ER
group, 2 additional cats only required insulin for
2 weeks (1 cat between weeks 10 and 12 and the other
between weeks 14 and 16).
Body Weight
In the exenatide ER group, body weight decreased in
6 cats (40%; median, 0.22 kg [3.3%]; range, 0.14
to 0.64 kg [2.6 to 14.5%]), increased in 8 (53.3%;
median, +0.89 kg [+18.4%]; range, +0.20 to +1.50 kg
[+3.4 to +21.1%]), and did not change in 1 (6.7%)
during the study period. In the placebo group, body
weight decreased in 2 cats (13.3%; (median, 0.28 kg
[5.9%]; range, 0.2 to 0.35 kg [4.4 to 7.3%])
and increased in 13 (86.7%; (median, +0.76 kg
[+21.6%]; range, +0.18 to +2.00 kg [+4.1 to +34.2%]).
Overall, median body weight increased in both groups
during the study; the increase was signiﬁcant in the pla-
cebo group (P = .002), but not in the exenatide ER-
treated cats (P = .084; Fig 4). Body condition score
increased signiﬁcantly in the placebo group (P = .002),
but not in the exenatide ER group (P = .058; Table 7).
In the exenatide ER group, among the 8 cats that
gained body weight, 3 went into remission, 4 achieved
good metabolic control and 1 did not achieve remission
or good metabolic control. In the same group, among
Table 5. Laboratory results and blood pressure measurements at baseline in diabetic cats treated with exenatide ER
vs. placebo.
Variable
Exenatide ER Placebo
Reference interval P-valueMedian (range) Mean (SD) Median (range) Mean (SD)
Haematocrit (%) 37 (29–47) 38 (4.9) 34 (25–47) 35 (6.7) 33–45 .268
Leukocytes (103/lL) 8.9 (3.2–20.5) 9.3 (4.0) 10.8 (4.8–22.1) 11.6 (5.1) 4.6–12.8 .165
Platelets (103/lL) 340 (207–525) 372 (108.5) 347 (156–672) 386 (143.2) 180–680 .923
Glucose (mg/dL) 329 (101–810) 383 (174.0) 428 (70–536) 384 (135.6) 72–162 .543
Fructosamine (lmol/L) 620 (402–883) 657 (162.4) 582 (438–878) 625 (134.0) 202–340 .604
Cholesterol (mg/dL) 256 (132–565) 279 (113.6) 267 (112–662) 300 (150.0) 101–263 .000
Triglycerides (mg/dL) 79 (26–350) 108 (96.8) 70 (35–3478) 578 (1104.2) 26–114 .537
Total protein (g/dL) 7.4 (6.4–11.4) 7.7 (1.2) 7.4 (6.3–8.3) 7.3 (0.6) 6.4–8.0 .369
Albumin (g/dL) 3.6 (3.1–4.1) 3.6 (0.3) 3.5 (2.7–4.4) 3.6 (0.4) 3.0–4.0 .760
Urea (mg/dL) 30.0 (17.6–52.1) 30.3 (10.0) 29.1 (21.6–37.2) 28.9 (5.8) 20.7–35.3 .494
Creatinine (mg/dL) 1.1 (0.9–1.9) 1.2 (0.3) 1.2 (0.6–1.7) 1.1 (0.3) 1.1–1.8 .460
Sodium (mEq/L) 157 (145–165) 157 (5.5) 158 (145–165) 157 (4.9) 158–165 .848
Chloride (mEq/L) 118 (99–126) 116 (7.4) 116 (105–121) 114 (5.1) 121–131 .280
Potassium (mEq/L) 4.7 (4.3–5.4) 4.7 (0.3) 4.8 (3.4–5.9) 4.8 (0.8) 3.8–5.4 .690
Phosphorus (mg/dL) 4.5 (2.7–6.5) 4.5 (0.9) 4.2 (2.5–5.0) 4.1 (0.7) 2.8–5.6 .130
Calcium (mg/dL) 10.3 (1.1–11.9) 9.8 (2.5) 10.4 (9.3–11.9) 10.4 (0.7) 9.6–11.2 .810
Bilirubin (mg/dL) 0.09 (0.02–0.43) 0.13 (0.1) 0.08 (0.01–0.43) 0.11 (0.1) 0–0.2 .747
ALP (U/L) 50 (30–112) 54 (21.9) 49 (32–92) 54 (19.0) 16–43 .975
ALAT (U/L) 76 (34–424) 122 (119.3 87 (33–379) 110 (91.0) 34–98 .709
ASAT (U/L) 29 (19–215) 45 (49.2) 41 (17–133) 48 (29.9) 19–44 .184
DGGR-Lipase (U/L) 25 (11–92) 29 (22.8) 23 (13–48) 25 (11.7) 8–26 .734
Spec fPL (lg/L) 2.2 (0.6–41.8) 6.6 (11.0) 3.0 (0.6–16.8) 4.6 (4.4) >5.3 .878
T4 (lg/L) 1.5 (0.7–2.4) 1.5 (0.5) 1.4 (0.5–1.8) 1.3 (0.5) <3.5 .434
IGF-1 (ng/mL)* 372 (227–1163) 524 (303.5) 405 (167–1041) 419 (223.6) <1000 .408
UPC* 0.22 (0.08–1.04) 0.31 (0.3) 0.2 (0.1–1.2) 0.3 (0.3) ≤0.40 .913
SAP (mm Hg)* 144 (96–224) 153 (42.2) 145 (85–189) 141 (30.1) 80–160 .573
SD, standard deviation; ALP, alkaline phosphatase; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; UPC, urine
protein-to-creatinine ratio; SAP, systolic arterial pressure.
*IGF-1, UPC, and SAP were increased in 3, 3, and 4 cats of the exenatide ER group, respectively, and in 1, 4, and 3 cats of the placebo
group, respectively.
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the 6 cats that lost body weight, 2 went into remission
and 4 achieved good metabolic control. One additional
cat had stable body weight and achieved remission. In
the placebo group, among the 13 cats that gained body
weight, 1 cat went into remission, 7 achieved good
metabolic control and 5 did not achieve remission or
A
B
Fig 2. Serum concentration of Spec fPL (A) and DGGR-lipase
(B) in exenatide ER- and placebo-treated cats during the 16-week
study period. Medians are shown. Dashed lines identify the refer-
ence interval. There were no diﬀerences between the groups.
Fig 3. Dot plots of median insulin dose administered per kg body
weight per day in cats receiving exenatide ER or placebo. Hori-
zontal lines mark the group medians.
Table 6. Onset of remission in diabetic cats treated
with exenatide ER or placebo (P = .167).
Onset of remission
Exenatide ER
(number of cats)
Placebo
(number of cats)
0–6 weeks after discharge 0 0
7–10 weeks after discharge 2 3
11–16 weeks after discharge 4 0
Fig 4. Body weight of cats of the exenatide ER and placebo
groups at baseline and week 16. Horizontal lines indicate the med-
ian body weight.
Table 7. Body condition score (BCS) in diabetic cats
treated with exenatide ER or placebo at baseline (week
0) and at week 16. Within each group, cats are divided
according to their body weight at week 16, which is
compared to week 0 and reported as increased,
decreased, or no change.
Group
Body weight
after 16 weeks
Number
of cats
BCS (1–9)
Week 0 Week 16
Exenatide ER Increased 2 4 5
1 4 6
2 5 5
2 5 6
1 7 8
Decreased 2 4 4
2 5 5
1 6 6
1 6 5
No change 1 5 5
Placebo Increased 1 3 4
1 3 5
3 4 5
3 5 6
2 6 6
1 6 8
1 7 8
1 7 9
Decreased 2 5 5
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good metabolic control. In the same group, the 2 cats
that lost body weight achieved remission. In the exe-
natide ER group, remission or metabolic control was
not associated with changes in body weight (P = 1.000).
The analysis was not performed in the placebo group
because of the small number of cats that lost body
weight.
Discussion
In humans with type 2 DM, exenatide ER administra-
tion generally is well tolerated, but transient mild gas-
trointestinal adverse eﬀects, which may in part be due to
decreased gastric emptying, frequently are
reported.5,6,21,22 Gastrointestinal adverse eﬀects of exe-
natide ER have been described recently in healthy cats15
and were commonly observed in these diabetic cats trea-
ted with the GLP-1 analogue, but the frequency of
adverse eﬀects was not signiﬁcantly higher than in the
placebo group. In these diabetic cats treated with exe-
natide ER, the adverse eﬀects usually were mild and
self-limiting, which is in agreement with ﬁndings in
other species.3 Increased duration of sleeping and hiding
in dark areas frequently were reported by owners of dia-
betic cats treated with exenatide ER, but these behaviors
were observed in the placebo group as well. Because
adverse eﬀects were not associated with exenatide ER in
the present study and none was moderate to severe or
long-lasting, we believe the GLP-1 analogue can be
safely used in diabetic cats. Of note, injection site irrita-
tion as well as nodular, eosinophil-rich, granulomatous
panniculitis at the injection site of exenatide has been
described in humans.23,24 To date, dermatologic irrita-
tion has not been reported in cats.11,13,15 Skin nodules
that were identiﬁed in 1 of our diabetic cats were likely
unrelated to exenatide ER injections. The lesions were
nonpruritic, 5 to 10 cm from the injection site, and diag-
nosed histologically as histiocytic panniculitis.
There have been concerns about incretin-based thera-
pies and pancreatitis in humans, but studies did not ﬁnd
a signiﬁcant association.25,26 The Food and Drug
Administration and the European Medicines Agency
recently stated that it is currently unclear whether there
is a causal relationship between incretin-based drugs
and pancreatitis.27 To our knowledge, a possible associ-
ation between incretin-based treatment and pancreatitis
in cats has not been investigated. Previous investiga-
tions showed that many cats with DM may have sub-
clinical pancreatitis.28,29 In our study, some cats treated
with exenatide ER had clinical signs compatible with
pancreatitis that included decreased appetite and vomit-
ing, but only 1 (8.3%) cat with normal baseline Spec
fPL and DGGR-lipase concentrations had an increase
in Spec fPL concentration during treatment. In our
study, to identify a signiﬁcant diﬀerence for pancreatitis
based on increased Spec fPL and assuming a 10%
prevalence caused by exenatide ER, sample size should
have been approximately 50 cats per group according
to a statistical power calculation.
An increase in serum creatinine concentration has
been reported in some humans treated with GLP-1
analogues, which suggests that renal failure may occur
or worsen during treatment. Based on this information,
exenatide treatment is not recommended, particularly in
human patients with severe renal impairment.h In the
present study, the increase in serum creatinine concen-
tration did not diﬀer between the 2 groups. In most
cats, serum creatinine concentrations stayed within the
normal range. However, diabetic cats with relevant kid-
ney disease were excluded; it is therefore possible that
an increase in serum creatinine concentration would
have occurred if diabetic cats with renal failure had
been included. The signiﬁcant increase of creatinine
observed in either group, although not above the refer-
ence range, might be explained by the fact that body
weight, and possibly muscle mass, increased in most
cats during insulin treatment.
An investigation of type 2 diabetic humans receiving
insulin glargine and short-acting exenatide or placebo
showed that the incidence of hypoglycemic episodes was
similar in both groups.30 In healthy cats treated with
exenatide ER, hypoglycemia was observed, whereas
clinical evidence of hypoglycemia did not occur.13 Simi-
larly, in the present study hypoglycemia was a common
ﬁnding, but there was no diﬀerence between the 2
groups. Clinical signs of hypoglycemia were observed in
2 cats of the exenatide ER group. Because these were 2
single episodes that were short-lived and there was no
diﬀerence compared with placebo, we hypothesize that
exenatide ER is safe when used in conjunction with
insulin to treat diabetic cats.
Compared with the results of other studies of diabetic
cats, the remission rates in the present investigation were
relatively low in both groups. Other studies have fol-
lowed diabetic cats for longer periods of time (eg
6 months) than our study (4 months),31,32 and it there-
fore is possible that more cats would have achieved
remission if the study had been longer. In addition, it is
known that the rate of remission is higher if diabetic cats
have received corticosteroids before diagnosis of DM.19
In the present study, cats with prior corticosteroid
administration were not included, whereas in 1 study
with high remission rate such cats were included.33 This
diﬀerence in selection criteria may explain at least in part
the diﬀerent remission rates. Furthermore, our deﬁnition
of remission was the maintenance of euglycemia without
insulin treatment for 4 weeks, whereas another study
deﬁned remission as 2 weeks of euglycemia without insu-
lin.33 If we had used this latter deﬁnition, there would
have been 2 additional cats in remission in the exenatide
ER group (but none in the placebo group) and thus, the
rate of remission would have increased from 40% to
53.3% (8 of 15 cats). A recent literature review on feline
diabetes suggested adopting the deﬁnition of diabetic
remission used in the present study.34
In humans with type 2 DM, exenatide ER once
weekly was superior to other GLP-1 analogues in con-
trolling blood glucose concentrations.5,6 Exenatide ER,
in addition to PO administered antidiabetic agents, also
was able to provide better glycemic control than insulin
detemir.35 The present study shows that the percentage
of cats that achieved good metabolic control was higher
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in the exenatide ER group than in the placebo group
(93.3% vs. 66.7%, respectively) when cats in remission
were grouped together with those with good metabolic
control. The diﬀerence between groups was not signiﬁ-
cant because of the relatively low number of cats.
According to the calculation of statistical power and
sample size and assuming the same percentages of
remission and good metabolic control, 28 instead of 14
cats per group would have been necessary to achieve
statistical signiﬁcance.g
In humans with type 2 DM, treatment with GLP-1
analogues is associated with weight loss, whereas insulin
glargine treatment is associated with weight gain.35
Weight loss was described in healthy cats during treat-
ment with exenatide or liraglutide.12,14 In our study, a
signiﬁcant weight gain and increase in BCS were
observed in cats of the placebo group, likely due to the
anabolic eﬀect of insulin treatment, but the increase
was not signiﬁcant in the exenatide ER group. Preven-
tion of weight gain is advised in diabetic cats with a
high BCS, whereas weight gain to normalize body con-
dition is preferable for diabetic cats with low BCS. In
general, exenatide ER administration was linked to
increased BCS in cats with low baseline BCS, but not in
cats with high baseline BCS. In humans treated with
GLP-1 analogues, weight control can be attributed to a
reduction in appetite because of increased satiation and
a delay in gastric emptying.21,36 In cats of our study
treated with exenatide ER weight control was not asso-
ciated with remission or metabolic control.
Our study had some limitations including the lack of
veterinarian blinding and the relatively low number of
cats. Signiﬁcant diﬀerences for rates of remission and
good metabolic control may have been observed with a
larger number of diabetic cats. Furthermore, the follow-
up period was set at 4 months and it is possible that
more cats would have achieved remission or good meta-
bolic control if a longer study period had been chosen.
In addition, the 2 cats with increased IGF-1 might have
had acromegaly. However, compatible clinical signs,
abdominal organ enlargement, or pituitary gland abnor-
malities were not detected and both cats achieved long-
lasting remission. The IGF-1 concentration was mea-
sured again at the end of the study and was normal in
1 cat and remained increased in the other. An IGF-1
concentration above the cutoﬀ (>1000 ng/ml) currently
is considered highly suspicious for acromegaly.37 There-
fore, although compatible clinical ﬁndings were not doc-
umented, the hypothesis of acromegaly could not be
entirely excluded in both cats. Finally, it is also worth
noting that costs of exenatide ER might limit its use,
and a month of treatment using the present protocol
costs approximately $150 USD.
In summary, exenatide ER was not associated with
local or systemic adverse eﬀects and can be safely used in
diabetic cats. Exenatide ER treatment does not result in
a signiﬁcant increase in body weight. Our study also sug-
gests that, should there be an additional signiﬁcant bene-
ﬁcial eﬀect of exenatide ER in insulin-treated cats on
rate of remission and good metabolic control, it would
likely be of a magnitude of approximately 20% and
30%, respectively. These results enable calculation of
statistical power and sample size for a deﬁnitive study.
Footnotes
a http://vetmed.tamu.edu/gilab/service/assays/pli
b NationWide, Specialist Laboratories, Cambridge, UK
c Lantus, Sanoﬁ Aventis, Meyrin, Switzerland
d DM Purina Veterinary Diets; Medical Solution, Steinhausen,
Switzerland
e Bydureon; Amylin Pharmaceuticals, San Diego, CA
f Body condition chart (cat); Nestle Purina, St. Louis, MO
g SPSS 18.0; SPSS, Chicago, IL
h http://www.fda.gov/safety/MedWatch/SafetyInformation/
SafetyAlertsforHumanMedicalProducts/ucm188703.htm
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